跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 12 条关于
“IDE574”
全部
12
临床试验
2
药物
1
机构
0
资讯
9
9个月前
IDEAYA Biosciences Submits IND for First-in-Class KAT6/7 Dual Inhibitor IDE574 Targeting Breast and Lung Cancers
9个月前
IDEAYA Biosciences Completes Enrollment in Pivotal Uveal Melanoma Trial, Advances Novel ADC Program
去年
IDEAYA Biosciences Licenses Biocytogen's B7H3/PTK7 Bispecific ADC for Solid Tumors
去年
IDEAYA Nominates IDE034, a First-in-Class B7H3/PTK7 Bispecific ADC, as Development Candidate
去年
IDEAYA Nominates IDE034, a First-in-Class B7H3/PTK7 Bispecific ADC, as Development Candidate
9个月前
IDEAYA Biosciences Receives FDA Clearance for First-in-Class Bispecific ADC IDE034 Targeting Multiple Solid Tumors
9个月前
FDA Clears First-in-Class Bispecific ADC IDE034 for Phase 1 Trial in Multiple Solid Tumors
去年
IDEAYA Biosciences' Werner Helicase Inhibitor IDE275 Cleared for Phase 1 Trial in MSI-High Solid Tumors
去年
IDEAYA's WRN Inhibitor IDE275 Shows Promise for MSI-H Cancers, Featured in AACR 2025 Oral Presentation